Skip to main content

Table 2 Clinical trials of low-dose vasopressin in vasodilatory shock states

From: Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology

Reference Year Trial n Patients Findings
[4] 1997 Case series 5 Septic shock A, B, C
[3] 1997 Matched cohort 19 Septic shock A, B, D in septic group
    12 Cardiogenic shock  
[5] 1999 RCT 10 Septic shock – trauma A, B
[2] 2000 RCT 24 Septic shock A, B, C, D
[94] 2001 Retrospective 60 Septic and postcardiotomy shock A, B, ↓ CI
[95] 2001 Prospective, case-controlled 16 Septic shock A, B, C
[7] 1998 Retrospective case series 40 Postbypass vasodilatory shock A, B, D
[6] 1997 RCT Placebo: N/S 10 Vasodilatory shock post-LVAD implant A, B in treatment arm; D in all
[8] 1999 Case series 20 Vasodilatory shock post-cardiac transplant A, B
[9] 1999 Case series 11 Pediatric – vasodilatory shock postbypass A, B, D
[10] 2000 Retrospective case series 50 Vasodilatory shock post-LVAD implantation A, B
[69] 2002 Retrospective 41 Postcardiotomy shock A, B
[11] 1999 Case series 10 Organ donors with vasodilatory shock A, D  
[68] 2000 Case series 7 Milrinone – hypotension A, B, C
  1. Findings are classified as follows: A, increase in blood pressure; B, decrease or discontinuance of catecholamines; C, increase in urine output; and D, low plasma vasopressin levels in subjects. CI, cardiac index; LVAD, left ventricular assist device; N/S, normal saline; RCT, randomized controlled trial.
\